跳至主要内容
临床试验/CTRI/2021/05/033552
CTRI/2021/05/033552已完成未知

Comparative efficacy of Lorazepam and Risperidone in Cannabis InducedPsychotic Disorder - CELRCIPD

Government medical college and hospital Chandigarh0 个研究点目标入组 40 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients fulfilling the diagnostic criteria for cannabis induced psychotic disorder as
  • per DSM-5.
  • 18-65 years old Male patients.
  • Patients willing for admission in ward for treatment.
  • Patients who test positive for cannabinoids on urine screening.
  • Patients with a reliable informant.
  • Patients willing to give consent.

排除标准

  • Patients with comorbid dependence on other substances except caffeine and nicotine.
  • Patients having current comorbid major mental illness.
  • Patients with a history of medical/physical illness where the use of Lorazepam/
  • Risperidone is contraindicated. For e.g. chronic liver disease, chronic kidney disease,
  • chronic lung disease, head injury etc.
  • History of hypersensitivity to Lorazepam/ Risperidone.

研究者

发起方
Government medical college and hospital Chandigarh

相似试验